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HTLV- I INFECTION IS NOT ASSOCIATED WITH A HIGHER RISK OF DEATH IN PERUVIAN  
HIV-INFECTED PATIENTS
Jaime A. COLLINS(1), Adrián V. HERNÁNDEZ(2), José A. HIDALGO(1), Raúl SALAZAR (1) & the Almenara Hospital AIDS Working Group*
SUMMARY
Limited and contradictory information exists regarding the prognosis of HIV/HTLV-I co-infection. Our goal was to estimate the 
effect of HTLV-I infection on mortality in HIV-infected patients at a HIV reference center in Peru. We studied a retrospective cohort 
of HIV-infected patients, who were exposed or unexposed to HTLV-I. Exposed patients were Western Blot (WB) positive for both 
retroviruses. Unexposed patients were WB positive for HIV, and had least one negative EIA for HTLV-I. These were selected among 
patients who entered our Program immediately before and after each exposed patient, between January 1990 and June 2004. Survival 
time was considered between the diagnosis of exposure to HTLV-I and death or censoring. Confounding variables were age, gender, 
baseline HIV clinical stage, baseline CD4+ T cell count, and antiretroviral therapy. We studied 50 exposed, and 100 unexposed 
patients. Exposed patients had a shorter survival compared to unexposed patients [median survival: 47 months (95% CI: 17-77) vs. 
85 months (95% CI: 70-100), unadjusted p = 0.06]. Exposed patients had a higher rate of mortality compared to unexposed patients 
(HIV/HTLV-I (24/50 [48%]) vs. HIV only (37/100 [37%]), univariable p = 0.2]. HTLV-I exposure was not associated to a higher risk 
of death in the adjusted analysis: HR: 1.2 (0.4-3.5). AIDS clinical stage and lack of antiretroviral therapy were associated to a higher 
risk of dying. In conclusions, HTLV-I infection was not associated with a higher risk of death in Peruvian HIV-infected patients. 
Advanced HIV infection and lack of antiretroviral therapy may explain the excess of mortality in this population.
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INTRODUCTION
The effect of the infection with the human T-lymphotropic virus type 
I (HTLV-I) on the progression or survival of human immunodeficiency 
virus (HIV) infection has not been studied extensively. These effects of 
the HIV/HTLV-I co-infection remain controversial in spite of an observed 
strong activation of cytokines that promote HIV infection2,8. 
Peru is an endemic area for HTLV-I infection. Its presence is well 
documented, especially in some ethnic groups (e.g. Quechuas, Mestizos, 
Blacks), and groups with risky sexual behavior (e.g. commercial 
sex workers)20,23,24. HIV/HTLV-I co-infection has previously been 
reported in Peru, and a shorter survival after onset of clinical acquired 
immunodeficiency syndrome (AIDS) was described in co-infected men16. 
We aimed to determine the effect of HTLV-I infection on survival of HIV-
infected patients from a reference center in Peru, based on a long-term 
retrospective, observational study, with a larger number of patients than 
most of the previously published studies. 
METHODS
We performed a retrospective cohort study with HIV-infected 
patients exposed and unexposed to HTLV-I. Patients were identified 
from the Almenara General Hospital HIV database, Lima, Peru, between 
January 1990 and June 2004. All HIV-infected patients were diagnosed 
with enzyme immunoassay (EIA) (Abbott, USA) and Western Blot tests 
(DAVIH-Blot, Cuba or Sanofi Pasteur, France). Exposure to HTLV-I 
was diagnosed with positive EIA (Sanofi Pasteur, France or Abbott, 
USA) and Western Blot (Cambridge Biotech, USA or DAVIH-Blot, 
Cuba) tests for HTLV-I. Patients unexposed to HTLV-I had at least one 
negative result to EIA HTLV-I. The HTLV test was performed at the 
time of referral to the HIV clinic. Two unexposed patients were selected 
per each exposed patient. The controls were chosen immediately before 
and after each exposed patient on our HIV database. All matched 
controls were chosen within one month of the presentation of the 
cases. Assuming a proportion of 50% of exposed patients and 80% of 
unexposed patients alive at 48 months6, a 20% of lost to follow-up, an 
alpha level of 0.05 and a power of 90%, we needed at least to have 43 
exposed patients and 86 unexposed patients. 
HIV transmission in Peru is mainly by sexual contact, and the 
intravenous-drug transmission is rare19. None of our patients had history 
of intravenous drug use. HCV prevalence in Peru is low in both the general 
population14 and risk groups, such as HIV patients (4% in our institution, 
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Raul Castillo, unpublished data), and health workers10. Therefore we did 
not include the HCV status in our analysis.
Survival time was considered from the time of referral for both 
the exposed and unexposed groups until death/censoring or date of the 
study end (i.e. October 31, 2004). We included other characteristics as 
confounding variables: age, gender, baseline HIV clinical stage1, baseline 
CD4+ T cell count, and history of antiretroviral therapy. Data regarding 
age, HIV clinical stage and CD4+ T cell count were recorded at the 
moment of serological evidence of HTLV-I infection. We did not have 
information about the time of HIV or HTLV-I seroconversion. Further, we 
did not include information on HIV viral load because half of the patients 
were seen when viral load was not commercially available (i.e. first half 
of the study period). All included patients had the same probability to 
receive highly active antiretroviral therapy (HAART) according to clinical 
stage, CD4+ T cell count and viral load. However, some patients were 
already receiving HAART. For these cases, we considered a CD4+ T 
cell count prior to initiation of HAART. Antiretroviral therapy categories 
were: no HAART (no antiretroviral therapy or HAART < 3 months) and 
HAART > 3 months. 
We used the X2 or Fisher exact tests for comparison of categorical 
variables, and Student´s t test for continuous variables (2-sided p values). 
Survival analysis was performed with the Kaplan-Meier method. A 
univariable Cox proportional hazards model was used to evaluate the 
independent effect of each variable (age, gender, baseline HIV clinical 
stage, baseline CD4+ T cell count, and history of antiretroviral therapy) on 
survival. We then evaluated the independent effect of HTLV-I infection on 
survival after adjustment for confounding variables. Statistical analyses 
were performed using SPSS for Windows, version 11.0. Sample size 
calculation was performed with the NCSS-PASS 2007 software (NCSS, 
Kaysville, Utah, USA)
RESULTS
During the period between January 1990 and June 2004, a total 
of 1456 HIV-infected patients were tested for HTLV infection with 
EIA, and 92 patients (6%) were HTLV-I/II positive. From this group, 
available WB tests revealed HTLV-I co-infection in 68 patients (5%) 
and HTLV-II co-infection in one patient. Of these 68 patients with 
HIV/HTLV-I co-infection, 50 were available for analysis. The patient 
with HIV/HTLV-II co-infection was excluded of the study. One 
hundred HIV-infected patients unexposed to HTLV were selected as 
comparison group. 
The characteristics of exposed and unexposed HIV-positive patients 
to HTLV-I are shown in Table 1. Exposed patients had a significant 
higher proportion of males (92% vs. 75%, p = 0.01), and were older than 
unexposed patients (mean age: 46 vs. 38 years, p < 0.001). No differences 
were observed between groups in baseline CD4+ T cell count, baseline 
HIV clinical stage, and antiretroviral therapy. The comparison of CD4+ 
T cell count was done with 50% (n = 19) and 72% (n = 49) of exposed 
and unexposed patients, respectively. 
The median survival for the entire cohort was 84 months (95% CI: 76-
92), and the survival probability at five years of follow-up was 62% (42% 
exposed, 70% unexposed). Median survival for exposed and unexposed 
patients were 47 months (17-77), and 85 months (70-100), respectively 
(unadjusted p = 0.06). Exposed patients had a higher rate of mortality 
compared to unexposed patients (HIV/HTLV-I (24/50 [48%]) vs. HIV 
only (37/100 [37%]), univariable p = 0.2). In patients without AIDS at 
baseline (n = 75), HIV/HTLV-I co-infected patients died more frequently 
and had higher proportion of cryptococcosis, wasting syndrome and 
toxoplasmosis than HIV infected patients, although differences were 
not significant (p > 0.05 for all comparisons) (Table 2). However, the 
proportion of pneumocystosis, tuberculosis and systemic Non-Hodgkin 
lymphoma was higher in the HIV alone group. Causes of death could 
not be identified because these were not specified in the clinical records. 
All deaths occurred at the beginning of the 1990s.
Table 1
Characteristics of HIV-infected patients with or without HTLV-I co-infection
Variable
HIV/HTLV-I co-infection
Yes 
(n = 50)
No 
(n = 100)
Total 
(n = 150)
p values
Age (years)
Mean (SD) 46 (12) 38 (10) 41 (11) < 0.001
CD4+ T cell (cell/μL)
Mean (SD) 130 (123) 135 (137) 134 (133) 0.9
Gender (n, %)
Male 46 (92) 75 (75) 121 (87) 0.01
HIV clinical stage (n, %)
AIDS 28 (56) 47 (47) 75 (50) 0.3
No AIDS 16 (32) 45 (45) 61 (41)
Not available 6 (12) 8 (8) 14 (9)
Antiretroviral therapy (n, %)
HAART 22 (44) 53 (53) 75 (50) 0.5
No HAART 24 (48) 38 (38) 62 (41)
Not available 4 (8) 9 (9) 13 (9)
SD: Standard Deviation
Table 2
Progression to death or first indicator condition of AIDS in HIV patients 
without AIDS at baseline
Condition HIV/HTLV-I (n = 22) HIV alone (n = 53)
N % N %
Death 7 32 7 13
Cryptococcosis 2 9 2 4
Wasting syndrome 2 9 3 6
Toxoplasmosis 1 5 0 0
Pneumocystosis 0 0 2 4
Tuberculosis 0 0 8 15
sNHL 0 0 1 2
We included six patients in the HIV/HTLV-I group and eight patients in the 
HIV alone group whose HIV clinical stage was not available; sNHL: Systemic 
Non-Hodgkin Lymphoma; p > 0.05 for all comparisons between HIV/HTLV-I 
and HIV alone groups.
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In the univariable analysis, HIV patients with the HTLV-I infection 
had a higher risk of death in comparison to patients without the HTLV-I 
infection (HR 1.6; 95% CI 1.0-2.8; p = 0.06). Age > 40 years, CD4+ < 
100 cell/μL, AIDS, and no HAART were also directly associated with 
death (Table 3). Male gender was not associated with death (HR 1.7; 
0.8-3.6). In multivariable analysis, HTLV-I exposure was not associated 
with death (HR 1.2; 0.4-3.6). Figure 1 shows the adjusted survival curves 
for the HIV/HTLV-I and HIV alone groups from the Cox analysis. As 
expected, AIDS stage and lack of HAART were independently associated 
with death. There was no effect modification of HIV/HTLV-I co-infection 
on mortality according to HAART treatment (p for interaction = 0.3). 
Within the group of patients with confirmed HIV/HTLV-I co-
infection, we did not find cases of clinical conditions associated to 
HTLV-I. 
DISCUSSION
HTLV-I infection was not associated with a higher risk of death in 
Peruvian HIV patients in comparison to patients with HIV infection alone, 
after adjustment for the main confounding variables. Information from 
medical records for up to 14 years of follow up was reviewed. Advanced 
HIV infection and lack of antiretroviral therapy may partly explain the 
excess of mortality on co-infected HIV/HTLV-I patients. Age was not 
associated with higher mortality rate. 
 
Several retrospective studies have evaluated the effect of HTLV-I 
infection on survival of HIV patients4,6,12,16,18,22. Most of them 
suggested that HIV/HTLV-I co-infection shortens the survival of these 
patients6,12,16,18,22. In contrast, a recent longitudinal retrospective study 
showed that the HTLV-I infection in persons with HIV was not associated 
with a shorter survival4. 
As it has been discussed2,4,7, incomplete demographic, laboratory 
and treatment data, lack of differentiation between HTLV-I and HTLV-
II12,16,18, and the lack of adjustment for confounding variables6,16 are key 
elements that make difficult the interpretation of the effect of HTLV-I 
on the survival of HIV patients. Moreover, special populations (e.g. 
intravenous drug users)18, and survival after onset of clinical AIDS16,22 
were considered in these reports. 
Further discrepancies between older and newer studies may be related 
to the use of HAART, because the proper therapy for HIV infection could 
mask the potentially additive effects of HIV/HTLV-I co-infection on disease 
progression7. However, we could not demonstrate this hypothesis. There 
was no effect modification on the effect of HIV/HTLV-I co-infection on 
mortality according to HAART treatment (p for interaction = 0.3). On the 
other hand, HAART has little impact on HTLV-I/II genome expression 
and this can increase the risk of developing neurological disease in HIV/
HTLV-I/II co-infected patients beginning HAART8. 
The absence of retroviral co-infection effect on survival in our study 
may be also related to the absence of clinical manifestations or syndromes 
associated with HTLV-I. This could be explained by the small size of the 
sample. In any case, this does not support the notion that HIV worsens 
the clinical presentation of HTLV-I, although there are some case reports 
suggesting this9,15. 
It is not clear whether the way of retroviral transmission (sexual 
vs. intravenous drug use) is related with HIV/HTLV-I co-infection 
progression. We cannot perform this analysis because almost all of our 
Table 3
Unadjusted and adjusted effect of HTLV-I exposure on the risk of death in HIV-
infected patients
Variable n
Unadjusted Adjusted
HR 95% CI% HR 95% CI
HIV / HTLV-I exposure
Yes 50 1.6 1.0 - 2.8 1.2 0.4 - 3.6
No 100
Age (years)
> 40 68 1.8 1.1 - 3.0 1.2 0.4 - 3.2
< 40 82
Gender
Male 121 1.7 0.8 - 3.6 1.4 0.4 - 4.6
Female 29
CD4+ T cell (cell/mL)
< 100 55 3.8 1.4 - 10.2 2.2 0.6 - 8.5
> 100 45
AIDS 
Yes 75 5.7 2.5 - 13.1 13.5 1.4 - 132.3
No 61
HAART
No 62 22.9 8.2 - 64.1  96.5 17.0 - 546.3
Yes 75
Fig. 1 - Survival by co-infection adjusted for age, gender, CD4+ T cells, AIDS stage and 
use of HAART.
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patients acquired retroviral co-infection through sexual transmission, the 
usual mode of HIV transmission in Peru19. 
 
On the other hand, SCHECHTER et al.21 reported high CD4+ T cell 
counts in HIV/HTLV-I co-infected patients in comparison with HIV 
infected patients. In addition, case reports11,13,17 or small case series3 
have described an accelerated progression to AIDS or the development 
of AIDS with this immunologic profile. In contrast, BESSINGER et 
al. 5 did not find an association between HIV/HTLV-I co-infection and 
high CD4+ T cell counts. Moreover, a recent large longitudinal study4 
showed that there were no significant differences in the presence of 
opportunistic infections, progression to AIDS or death between HIV/
HTLV-I co-infected and HIV infected patients. 
To gain some additional insight on the effect of the co-infection 
on progression of HIV, we compared HIV/HTLV-I and HIV patients 
diagnosed prior to the development of AIDS. The number of deaths and 
AIDS-defining conditions did not show significant differences (Table 2). 
Although the numbers are small, this finding is consistent with the report 
by BEILKE et al.4 and with our observation for the complete population. 
Our study has several limitations. First, dates of seroconversion 
were usually imprecise or unknown, so we were not able to identify true 
survival times. Second, the sample size is relatively small to reach definite 
conclusions on the effect of HTLV-I on survival of HIV patients. Third, 
26% of patients were excluded from the final analysis due to missing 
data on survival. Fourth, few confounding variables had a moderate 
amount of missing values (up to 33%), such as baseline CD4+ T cell 
count, baseline HIV clinical stage, and antiretroviral therapy. However, 
the overall study period reached 14 years of observation, longer than 
prior reports. Most of our patients received regular care for prolonged 
periods of time improving the quality of the information obtained, thus 
reducing the probability of information bias.
In conclusion, Peruvian patients with HIV/HTLV-I co-infection did 
not have higher risk of death than patients with HIV infection alone in the 
long term, after adjusting for the main confounding variables. HAART 
did not modify the effect of HIV/HTLV-I co-infection on mortality. 
Prospective cohorts with large number of patients may clarify the effect 
of HIV/HTLV-I co-infection on mortality. 
RESUMO
A infecção pelo HTLV- I não está associada a maior risco de morte 
em pacientes peruanos infectados pelo HIV
Existe informação limitada e contraditória sobre o prognóstico da co-
infecção pelo Vírus da Imunodeficiência Humana Tipo 1 (HIV-1) e Vírus 
Linfotrópico de Células T Humanas Tipo I (HTLV-I). Nosso objetivo foi 
estimar o efeito da infecção pelo HTLV-I na mortalidade de pacientes 
infectados pelo HIV-1 em Centro de Referência de HIV no Peru. Trata-se 
de uma coorte retrospectiva de pacientes infectados pelo HIV, expostos 
ou não expostos ao HTLV-I. Os pacientes expostos tiveram resultados 
positivos no Western Blot (WB) para ambos retrovírus. Os pacientes não 
expostos tiveram resultados positivos para o HIV-1 e pelo menos um teste 
de EIA negativo para o HTLV-I. Esses pacientes foram selecionados 
entre aqueles que entraram no nosso Programa imediatamente antes ou 
depois de cada paciente exposto, no período de janeiro de 1990 a junho 
de 2004. O tempo de sobrevida foi considerado entre o diagnóstico da 
exposição ao HTLV-I e a morte. As variáveis de confusão foram: idade, 
gênero, estágio clínico basal da infecção pelo HIV-1, contagem basal de 
células CD4, e terapia anti-retroviral. Estudamos 50 pacientes expostos 
e 100 não expostos. Os pacientes expostos tiveram menor sobrevida 
quando comparados aos não expostos [mediana de sobrevida: 47 meses 
(95% IC: 17-77) versus 85 meses (70-100), p não ajustado < 0.06]. Os 
pacientes expostos tiveram maior risco de morte quando comparados aos 
não expostos (HIV-1/HTLV-I (24/50 [48%]) versus HIV-1 só (37/100 
[37%]) p univariado = 0.2). A exposição ao HTLV-I não foi associada 
a maior risco de morte na análise ajustada: HR: 1.2 (0.4-3.5). O estágio 
clínico da infecção pelo HIV-1 e a ausência de terapia anti-retroviral 
foram associados a maior risco de morte. Em conclusão, a infecção pelo 
HTLV-I não foi associada a maior risco de morte em pacientes peruanos 
infectados pelo HIV-1. A infecção avançada pelo HIV-1 e a falta de terapia 
anti-retroviral podem explicar o excesso de mortalidade nesta população.
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